# Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma

> **NCT06242249** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shahid Beheshti University of Medical Sciences** · enrollment: 10 (estimated)

## Conditions studied

- Multiple Myeloma, Refractory

## Interventions

- **BIOLOGICAL:** Anti-BCMA CAR-NK

## Key facts

- **NCT ID:** NCT06242249
- **Lead sponsor:** Shahid Beheshti University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-30
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06242249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06242249, "Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06242249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*